Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

lso has an approved IND application for Panzem(R) in rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

    CONTACT:
    Ginny Dunn
    Associate Director, Corporate Communications & Investor Relations
    EntreMed, Inc.
    240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Product and process ... low abundance and are often “lost in the ... , Join presenters Dr. Rowel Tobias, Senior Scientist, ... Anders, Head of Quality at Nanotherapeutics, Inc., to ... can speed detection and quantitation while achieving the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... , July 10, 2014  Franciscan St. ... of capnography for respiratory monitoring outside the ... healthcare leaders in embracing state-of-the-art patient safety ... patients are breathing and can alert medical ... measuring the amount of carbon dioxide the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Calif., Feb. 23, 2011 The Clearity ... personalized treatment information to women with ovarian cancer, ... Executive Director, a new position for the organization. ... the foundation as it increases its capacity to ...
... 2011 Ingenuity® Systems, a leading provider of ... today announced a research collaboration with Covance Genomics ... data analysis. Covance Genomics Laboratory, a leading provider ... development industry, and Ingenuity will work together to ...
... , This release is available in ... technology requires computer capacities of increased efficiency at reasonable ... electronic components was increased constantly. In continuation of this ... of individual molecules. Researchers from the KIT Center for ...
Cached Biology Technology:The Clearity Foundation Hires Hillary Theakston as Executive Director 2The Clearity Foundation Hires Hillary Theakston as Executive Director 3Ingenuity Systems and Covance Collaborate to Support Next-Generation Sequencing Research 2Smallest magnetic field sensor in the world 2
(Date:7/11/2014)... have explored two different ways that allow unprecedented ... the formation of oxygen molecules in photosynthesis. The ... journal Nature Communications . , "The new ... for water oxidation, which are key components for ... of solar energy in fuels like hydrogen, ethanol ...
(Date:7/11/2014)... risk of kidney injury related to the use of ... of HES molecules, according to a report in ... Anesthesia Research Society (IARS). , The "total mass of ... cultured human renal proximal tubule cells (PTCs), concludes the ... University Hospital Wrzburg, Austria. Other factorssuch as differences ...
(Date:7/11/2014)... the marginal division of the striatum is also ... impact degree of substance P in the striatal ... Yu and his team, College of Biophotonics, South ... that substance P receptor, neurokinin 1 was highly ... of normal rats. Unilateral or bilateral injection of ...
Breaking Biology News(10 mins):Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... For the first time, a genetic link specific to ... a team of researchers from Memorial Sloan-Kettering Cancer Center, ... other institutions. The discovery was reported online today in ... in unchartered territory," said study author Kenneth Offit, MD, ...
... of nanopore technology aimed at more accurate and efficient DNA ... National Institutes of Health. The grants nearly $17 million ... the National Human Genome Research Institute (NHGRI),s Advanced DNA Sequencing ... of NIH. , "Nanopore technology shows great promise, but ...
... Sept. 6, 2013  Daniel P. Linskey, superintendent-in-chief of the ... Boston Marathon Bombings" at the 2013 IEEE International Conference on ... Linskey,s talk will focus on the aftermath of the ... his department and federal enforcement agencies that ultimately led to ...
Cached Biology News:Researchers uncover genetic cause of childhood leukemia 2New NIH awards focus on nanopore technology for DNA sequencing 2New NIH awards focus on nanopore technology for DNA sequencing 3New NIH awards focus on nanopore technology for DNA sequencing 4Boston Police Chief to Address Boston Marathon Bombings at IEEE Homeland Security Conference in Waltham, Mass., on 12 November 2
Mouse monoclonal antibody raised against a partial recombinant CAPG. NCBI Entrez Gene ID = CAPG...
Mouse monoclonal antibody raised against a partial recombinant PDE2A. NCBI Entrez Gene ID = PDE2A...
...
... sample is a complex protein sample, ... when used with ReadyPrep 2-D starter ... sample can be used as a ... and protocol before using more difficult ...
Biology Products: